- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07763665
Anti-inflammatory Effect of MgSO₄ in Patients With Moderate Traumatic Brain Injury by Measurming Nucleotide-binding Oligomerization Domain-Like Receptor Pyrin Domain-containing 3 (NLRP3) Inflammasome-a Multiprotein Complex
Anti-Inflammatory Effect of Magnesium Sulfate on the Outcomes of Patients With Moderate Traumatic Brain Injury.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Traumatic brain injury (TBI) remains a leading cause of mortality and long-term disability worldwide, disrupting both individual lives and healthcare systems. The pathophysiology of TBI is characterized by a biphasic process. The primary injury occurs at the moment of impact, resulting in immediate mechanical tissue disruption. This is followed by a complex cascade of cellular and molecular changes known as secondary brain injury, which develops hours to days later.
A cornerstone of this secondary injury pathway is neuroinflammation, driven by the activation of resident microglia and the infiltration of peripheral immune cells. Central to this inflammatory response is the assembly and activation of the Nucleotide-binding oligomerization domain-Like Receptor Pyrin domain-containing 3 (NLRP3) inflammasome-a multiprotein complex that triggers the maturation and release of potent pro-inflammatory cytokines, specifically interleukin-1β (IL-1β) and interleukin-18 (IL-18), accelerating neuronal apoptosis and blood-brain barrier dysfunction.
Magnesium sulfate (MgSO₄) has emerged as a promising neuroprotective candidate due to its multifaceted mechanism of action. Primarily, magnesium acts as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, thereby mitigating glutamate-mediated excitotoxicity. Emerging molecular evidence further indicates that magnesium exerts potent anti-inflammatory effects by downregulating nuclear factor kappa B (NF-κB) activation and directly inhibiting the assembly of the NLRP3 inflammasome. Consequently, evaluating the clinical and molecular efficacy of MgSO₄ in TBI patients could offer a viable therapeutic pathway to suppress secondary neuroinflammation and optimize neurological recovery.
NLRP3 Inflammasome is a multiprotein complex consisting of three core components:
- Sensor (NLRP3)
- Adaptor (ASC)
- Effector (Caspase-1)
Its activation is regulated by a two-signal framework:
- Priming (Signal 1): Activates the nuclear factor kappa B(NF-κB) pathway to produce baseline NLRP3 components and inactive proteins (Pro-IL-1β, P ro-IL-18 andPro-IL-6).
- Activation (Signal 2): Triggered by cellular stress signals (such as Ca 2+ influx, K efflux, and mitochondrial distress).
Active Caspase-1 processes cytokines into their potent active forms and triggers a inflammatory cell death.
Magnesium sulfate (MgSO₄) has emerged as a promising neuroprotective candidate.
Magnesium sulfate exerts potent anti-inflammatory effects that can inhibit NLRP3 Inflammasome activation through 4 mechanisms:
- downregulating nuclear factor kappa B (NF-κB) activation and directly inhibiting the assembly of the NLRP3 inflammasome
- preventing extracellular Ca2+ influx and intracellular release
- Reducing K Efflux
- Preserving Mitochondrial Integrity
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 4
Contatti e Sedi
Contatto studio
- Nome: Ehab Samir, Assistant lecturer
- Numero di telefono: +201003078676
- Email: hobasamir12@gmail.com
Backup dei contatti dello studio
- Nome: Ghada Abolfadl, Prof.
- Numero di telefono: +201005802086
- Email: ghadafadl@aun.edu.eg
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Male and female patients aged 18 to 60 years.
- Sustained a closed head trauma with the study drug infusion initiated within 8 hours of the injury.
- TBI confirmed by history and clinical examination.
- Patients with moderate (GCS = 9-12) traumatic brain injury.
- Evidence of TBI confirmed by abnormalities consistent with trauma on CT scan upon admission (diffuse injury II-IV, evacuated and non-evacuated mass lesion, Marshall's CT Classification ).
- Hemodynamic stability at the time of enrollment.
Exclusion Criteria:
- Patient Refusal
- Prolonged and/or uncorrectable hypoxia (PaO₂ < 60 mmHg) or persistent hypotension (systolic blood pressure < 90 mmHg) at the time of randomization.
- Cardiopulmonary arrest.
- Concomitant spinal cord injury.
- Pregnant or lactating females.
- Penetrating head injury.
- Associated other extra-cranial trauma or systemic polytrauma.
- Undergoing surgical interventions during the study.
- Pre-existing severe cardiac arrhythmia, heart block, or significant myocardial damage (documented on ECG).
- Known history of chronic renal failure or abnormal baseline renal function.
- Known hypersensitivity or allergic reaction to magnesium sulfate.
- Patients on chronic steroid therapy.
BMI>35 kg/m2.
-
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione fattoriale
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Group (A): Will receive intravenous magnesium sulfate MgSO₄.
32 patients will receive
|
evaluate the biochemical efficacy of Magnesium Sulfate (MgSO₄) as an anti-inflammatory therapeutic agent in patients suffering from moderate traumatic brain injury (TBI)
|
|
Sperimentale: Group (B): Will receive intravenous normal saline as a placebo.
32 patients Will receive intravenous normal saline as a placebo.
|
evaluate the biochemical efficacy of Magnesium Sulfate (MgSO₄) as an anti-inflammatory therapeutic agent in patients suffering from moderate traumatic brain injury (TBI)
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Measured by the change in serum concentrations of the NLRP3 inflammasome complex
Lasso di tempo: Measured by the change in serum concentrations of the NLRP3 inflammasome complex components from baseline (T₀) to 48 hours post-intervention (T₄₈), quantified via Enzyme-Linked Immunosorbent Assay (ELISA)
|
Molecular Anti-inflammatory Response: Measured by the change in serum concentrations of the NLRP3 inflammasome complex components from baseline (T₀) to 48 hours post-intervention (T₄₈), quantified via Enzyme-Linked Immunosorbent Assay (ELISA)
|
Measured by the change in serum concentrations of the NLRP3 inflammasome complex components from baseline (T₀) to 48 hours post-intervention (T₄₈), quantified via Enzyme-Linked Immunosorbent Assay (ELISA)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Glasgow Coma Scale (GCS) score
Lasso di tempo: day 7 post-injury and one month
|
Glasgow Coma Scale (GCS) score
|
day 7 post-injury and one month
|
|
Incidence of hypermagnesemia-related toxicity or drug-related adverse events
Lasso di tempo: 48 hours
|
measurement of magnesium sulfate on admission and post intervention
|
48 hours
|
|
ESR, CRP and serum Magnesium levels on admission (T₀) and 48 hours post-intervention (T₄₈)
Lasso di tempo: 48 hours
|
ESR, CRP and serum Magnesium levels on admission (T₀) and 48 hours post-intervention (T₄₈)
|
48 hours
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Ferite e lesioni
- Trauma craniocerebrale
- Trauma, sistema nervoso
- Lesioni cerebrali
- Lesioni cerebrali, traumatiche
- Composti di zolfo
- Preparati farmaceutici
- Prodotti chimici inorganici
- Soluzioni cristalloidi
- Soluzioni isotoniche
- Soluzioni
- Acidi zolfo
- Solfati
- Acidi solforici
- Composti di magnesio
- Solfato di magnesio
- Soluzione salina
Altri numeri di identificazione dello studio
- effect of MgSO₄ in TBI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .